News
-
Verona Pharma, which has been looking for a partner for its lead product RPL554, an inhaled phosphodiesterase 3 and phosphodiesterase 4 inhibitor for the treatment of asthma, COPD, and allergic rhinitis, announced that it has… Read more . . .
-
An article published in The Lancet on November 20, 2010 describes the case of a teen-aged boy who appeared to suffer from asthma exacerbations linked to emotional distress caused by his use of Facebook. His… Read more . . .
-
Researchers from the Medco Research Institute presented data at the 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) showing that clinicians are prescribing ICS/LABA combination treatment for two thirds of… Read more . . .
-
Having recently announced that it stands by its clinical trials after a former executive filed suit against the company for retaliatory termination after he raised concerns about the validity of studies conducted in Russia and… Read more . . .
-
A Phase 3 study of the Qnaze beclamethasone nasal spray from Teva has demonstrated that the product produced significant symptom relief compared to placebo, according to a Teva presentation at the 2010 Annual Meeting of… Read more . . .
-
According to the European Medicines Agency, Schering-Plough Europe (Merck) has withdrawn its marketing authorization application for its Zenhale mometesone furoate/formoterol fumarate MDI. The company said that it was unable to provide data requested by the… Read more . . .
-
Microdose Therapeutx will now be able to offer the Nexus6 SmartinhalerLive technology as an integral component of its electronic dry powder inhaler. The Nexus6 technology will allow the Microdose DPI to provide real-time reporting of… Read more . . .
-
Summit Biosciences has received almost $150k in qualifying therapeutic discovery project (QTDP) grants for development of its synthetic THC nasal spray. According to Summit, it will use the money to hire new personnel for the… Read more . . .
-
The Alberta Idealized Throat, a new cascade impactor induction port designed to represent conditions in the human throat better than the standard USP/Ph.Eur induction port, will be introduced by Copley Scientific at DDL 21. The… Read more . . .
-
Richard Hawkins, who founded Pharmaco, now PPD Development, has joined the board of directors of Texas-based inhalation drug development company Savara. The company is developing a number of dry powder aerosol medicines based on its… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden